149 related articles for article (PubMed ID: 35767124)
21. Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register.
Palareti G; Antonucci E; Legnani C; Mastroiacovo D; Poli D; Prandoni P; Tosetto A; Pengo V; Testa S; Ageno W;
BMJ Open; 2020 Nov; 10(11):e040449. PubMed ID: 33247017
[TBL] [Abstract][Full Text] [Related]
22. EvaluatioN of ApiXaban in strOke and systemic embolism prevention in patients with non-valvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM study.
Picard F; Van Ganse E; Ducrocq G; Danchin N; Falissard B; Hanon O; Belhassen M; Ginoux M; Lefevre C; Cotte FE; Mahé I; Steg PG
Clin Cardiol; 2019 Oct; 42(10):851-859. PubMed ID: 31313832
[TBL] [Abstract][Full Text] [Related]
23. Total costs of treating venous thromboembolism: implication of different cost perspectives in a Danish setting.
Nielsen A; Poulsen PB; Dybro L; Kloster B; Lorentzen A; Olsen J; Kümler T
J Med Econ; 2019 Dec; 22(12):1321-1327. PubMed ID: 31516054
[No Abstract] [Full Text] [Related]
24. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
[TBL] [Abstract][Full Text] [Related]
25. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
van Es N; Coppens M; Schulman S; Middeldorp S; Büller HR
Blood; 2014 Sep; 124(12):1968-75. PubMed ID: 24963045
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
[TBL] [Abstract][Full Text] [Related]
27. Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients.
Lutsey PL; Norby FL; Zakai NA; MacLehose RF; Chen LY; Shah S; Datta YH; Alonso A
Curr Med Res Opin; 2019 May; 35(5):837-845. PubMed ID: 30362847
[TBL] [Abstract][Full Text] [Related]
28. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
[TBL] [Abstract][Full Text] [Related]
29. Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.
Reynolds SL; Ghate SR; Sheer R; Gandhi PK; Moretz C; Wang C; Sander S; Costantino ME; Annavarapu S; Andrews G
Health Qual Life Outcomes; 2017 Jun; 15(1):128. PubMed ID: 28637460
[TBL] [Abstract][Full Text] [Related]
30. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
[TBL] [Abstract][Full Text] [Related]
31. Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older.
Manckoundia P; Nuemi G; Hacquin A; Menu D; Rosay C; Vovelle J; Nuss V; Baudin-Senegas C; Barben J; Putot A
Int J Environ Res Public Health; 2021 Apr; 18(9):. PubMed ID: 33922331
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
[TBL] [Abstract][Full Text] [Related]
33. Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis.
Sobieraj DM; Coleman CI; Pasupuleti V; Deshpande A; Kaw R; Hernandez AV
Thromb Res; 2015 May; 135(5):888-96. PubMed ID: 25795564
[TBL] [Abstract][Full Text] [Related]
34. Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort Study.
Rago A; Papa AA; Cassese A; Arena G; Magliocca MCG; D'Onofrio A; Golino P; Nigro G; Russo V
Am J Cardiovasc Drugs; 2019 Aug; 19(4):421-427. PubMed ID: 30838557
[TBL] [Abstract][Full Text] [Related]
35. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
[TBL] [Abstract][Full Text] [Related]
36. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A
PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695
[TBL] [Abstract][Full Text] [Related]
37. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
[TBL] [Abstract][Full Text] [Related]
38. Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review.
Gómez-Outes A; Lecumberri R; Suárez-Gea ML; Terleira-Fernández AI; Monreal M; Vargas-Castrillón E
J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):490-500. PubMed ID: 25802423
[TBL] [Abstract][Full Text] [Related]
39. Editor's Choice - Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials.
Chen J; Lv M; Wu S; Jiang S; Xu W; Qian J; Chen M; Fang Z; Zeng Z; Zhang J
Eur J Vasc Endovasc Surg; 2022 Mar; 63(3):465-474. PubMed ID: 34973879
[TBL] [Abstract][Full Text] [Related]
40. Thromboembolic Events While Taking Direct Oral Anticoagulants: An Analysis of Post-market WHO Database Reports from 2012 to 2020.
Mitrovic D; Emmens W; Naimi A; van der Mijle A; Veeger N; van Roon E; van den Bemt P
Clin Drug Investig; 2022 Jul; 42(7):593-598. PubMed ID: 35675030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
